Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $6.8571.

Several research firms have commented on NMRA. HC Wainwright dropped their price objective on shares of Neumora Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Mizuho reduced their target price on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research note on Thursday, June 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Tuesday, April 21st. Needham & Company LLC dropped their price target on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Finally, Guggenheim reaffirmed a “buy” rating and set a $14.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 31st.

Neumora Therapeutics Stock Performance

Shares of NASDAQ NMRA opened at $1.67 on Monday. Neumora Therapeutics has a 1-year low of $0.78 and a 1-year high of $3.65. The company has a debt-to-equity ratio of 0.75, a current ratio of 5.09 and a quick ratio of 5.09. The business’s 50 day moving average is $1.80 and its two-hundred day moving average is $2.18. The stock has a market capitalization of $309.42 million, a P/E ratio of -1.26 and a beta of 2.74.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02. As a group, research analysts expect that Neumora Therapeutics will post -0.93 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Invesco Ltd. grew its stake in shares of Neumora Therapeutics by 151.1% during the first quarter. Invesco Ltd. now owns 123,655 shares of the company’s stock valued at $124,000 after buying an additional 74,406 shares during the last quarter. AQR Capital Management LLC bought a new position in Neumora Therapeutics in the 1st quarter valued at $463,000. Russell Investments Group Ltd. grew its position in Neumora Therapeutics by 2,898.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 73,812 shares of the company’s stock valued at $56,000 after acquiring an additional 71,350 shares during the last quarter. Marshall Wace LLP purchased a new stake in Neumora Therapeutics in the second quarter worth $183,000. Finally, Federated Hermes Inc. increased its stake in Neumora Therapeutics by 10.4% in the second quarter. Federated Hermes Inc. now owns 314,119 shares of the company’s stock worth $230,000 after purchasing an additional 29,543 shares during the period. Hedge funds and other institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.